Well-established clinical methods, such as pancreatic transplantation, the infusion of islets of Langerhans, and more recently, the use of cellular drugs like Lantidra, have been central to therapeutic strategies aimed at restoring insulin production and improving glycemic control in patients whose β-cells have been destroyed by autoimmune processes in diabetes [45,46]. The gene discussed is INS; the disease is diabetes mellitus.